223 related articles for article (PubMed ID: 32883643)
1. Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors.
Xu Y; Zhang XJ; Li WB; Wang XR; Wang S; Qiao XP; Chen SW
Eur J Med Chem; 2020 Dec; 208():112780. PubMed ID: 32883643
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N, 6-diphenyl-5, 6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors.
Li J; Zhang W; Qiu Q; Zhou D; Feng Z; Tong Z; Wei J; Huang W; Li J; Qian H; Shi W
Chem Biol Drug Des; 2021 May; 97(5):1117-1128. PubMed ID: 33638254
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
Li Q; Li J; Cai Y; Zou Y; Chen B; Zou F; Mo J; Han T; Guo W; Huang W; Qiu Q; Qian H
Bioorg Med Chem; 2020 Aug; 28(15):115601. PubMed ID: 32631570
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents.
Cheng G; Wang Z; Yang J; Bao Y; Xu Q; Zhao L; Liu D
Bioorg Chem; 2019 Mar; 84():410-417. PubMed ID: 30554080
[TBL] [Abstract][Full Text] [Related]
5. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and in vitro Biological Evaluation of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors.
Li X; Zhang J; Zhao L; Yang Y; Zhang H; Zhou J
ChemMedChem; 2018 Jul; 13(13):1363-1368. PubMed ID: 29808961
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
[TBL] [Abstract][Full Text] [Related]
10. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
[TBL] [Abstract][Full Text] [Related]
11. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors.
Yang Y; Zhao L; Xu B; Yang L; Zhang J; Zhang H; Zhou J
Bioorg Chem; 2016 Oct; 68():236-44. PubMed ID: 27580186
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
14. Exploiting the 7-methylimidazo[1,5-a]pyrazin-8(7H)-one scaffold for the development of novel chemical inhibitors for Bromodomain and Extraterminal Domain (BET) family.
Yang Y; Chen P; Zhao L; Zhang F; Zhang B; Xu C; Zhang H; Zhou J
Bioorg Chem; 2019 Sep; 90():103044. PubMed ID: 31220668
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.
Fang L; Hu Z; Yang Y; Chen P; Zhou J; Zhang H
Bioorg Med Chem; 2021 Jun; 39():116133. PubMed ID: 33862375
[TBL] [Abstract][Full Text] [Related]
16. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer.
Jiang W; Wang X; Shu C; Hou Q; Yang K; Wu X
Bioorg Chem; 2022 Feb; 119():105575. PubMed ID: 34995979
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors.
Xu KY; Wang XT; Cheng L; Cui QH; Shi JT; Zhang LW; Chen SW
Bioorg Med Chem; 2023 Jan; 78():117152. PubMed ID: 36599264
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Thieno[2,3-
Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]